Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ford Motor Co F

Alternate Symbol(s):  F.P.D

Ford Motor Company is an automobile company. The Company develops and delivers Ford trucks, sport utility vehicles, commercial vans and cars and Lincoln luxury vehicles, along with connected services. Its Ford Blue segment includes the sale of Ford and Lincoln internal combustion engine (ICE) and hybrid vehicles, service parts, accessories, and digital services for retail customers. Ford Model e segment primarily includes the sale of electric vehicles, service parts, accessories, and digital services. Ford Pro primarily includes the sale of Ford and Lincoln vehicles, service parts, accessories, and services for commercial, government, and rental customers. Ford Next segment primarily includes expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. Ford Credit segment is comprised of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities.


NYSE:F - Post by User

Post by SophiaBrownon Jun 03, 2022 3:08am
151 Views
Post# 34728618

FSD will proceed with Phase2 of FSD-201 soon after clearance

FSD will proceed with Phase2 of FSD-201 soon after clearance
FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.

<< Previous
Bullboard Posts
Next >>